34
Views
3
CrossRef citations to date
0
Altmetric
LetterToEditor

Successful treatment with fenofibrate of autoimmune hepatitis in a patient with rheumatoid arthritis

&
Pages 235-236 | Accepted 03 Sep 2006, Published online: 12 Jul 2009

References

  • Alverez F., Berg P. A., Bianchi F. B. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929–38
  • Johnson P. J., McFarlane I. G., Williams R. Azathioprine for long‐term maintenance of remission in autoimmunehepatitis. N Engl J Med 1995; 333: 958–63
  • Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I. P., et al. Activation of human aortic smooth‐muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393: 790–3
  • Okamoto H., Kamatani N. Successful treatment with fenofibrate, a peroxisome proliferator activated receptor alpha ligand, for a patient with rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1002–3
  • Okamoto H., Iwamoto T., Kotake S., Momohara S., Yamanaka H., Kamatani N. Inhibition of NF‐kappaB signaling by fenofibrate, a peroxisome proliferator‐activated receptor‐alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 323–30
  • Cornwell P. D., De Souza A. T., Ulrich R. G. Profiling of hepatic gene expression in rats treated with fibric acid analogs. Mutat Res 2004; 549: 131–45

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.